THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and neuromyelitis optica (NMO), today
announced Opexa has been named one of the “Top 10 Advanced Therapy
Projects to Watch” by Elsevier Business Intelligence for the second
consecutive year. As part of this recognition, Neil K. Warma, Opexa’s
President and Chief Executive Officer, will present a company overview
at the Therapeutic Area Partnerships meeting taking place on November
19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on
Thursday, November 20 at 2:25 p.m. E.S.T.
"Selected companies have been screened using a strict set of judging
criteria for the Top 10 award and represent what our committees consider
among the most attractive opportunities the industry has to offer," said
Marc Wortman, Editorial Director, Therapeutic Area Partnerships.
"Winners have met rigorous criteria, including: unmet medical need,
market potential, diversity of indications, strong science, multi-level
partnering opportunities (biotech and pharma), potential for new
opportunities beyond initial indications and corporate stability.”
“We are honored to be chosen for the second year as one of the top ten
advanced therapies by Elsevier,” stated Mr. Warma. “We believe this
recognition speaks to the potential Tcelna® holds for the
treatment of secondary progressive MS, as well as to Opexa’s position as
a leader in the field of personalized medicine.”
About Opexa
Opexa is a biopharmaceutical company developing personalized
immunotherapies with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases, such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®,
is a personalized T-cell immunotherapy that is in a Phase IIb clinical
development program (the Abili-T trial) for the treatment of Secondary
Progressive MS. Tcelna is derived from T-cells isolated from the
patient’s peripheral blood, expanded ex vivo, and reintroduced
into the patients via subcutaneous injections. This process triggers a
potent immune response against specific subsets of autoreactive T-cells
known to attack myelin. Opexa’s mission is to lead the field of
Precision Immunotherapy® by aligning the interests of
patients, employees and shareholders.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Forward-Looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The
words "expects," "believes," "may," "intends," "potential" and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements do not constitute guarantees of future
performance. Investors are cautioned that forward-looking statements,
including without limitation statements regarding the safety, efficacy
and projected development timeline of drug candidates such as Tcelna®
and OPX-212 constitute forward-looking statements. These forward-looking
statements are based upon our current expectations and involve
assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from
those anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include without limitation our
ability to raise additional capital to continue our development
programs, our ability to successfully develop potential products such as
Tcelna, our ability to obtain, maintain and protect intellectual
property rights (including for Tcelna and future pipeline candidates
such as OPX-212), as well as other risks associated with the process of
discovering, developing and commercializing drug candidates that are
safe and effective for use as human therapeutics. These and other risks
are described in detail in our SEC filings, including our Annual Report
on Form 10-K for the year ended December 31, 2013 and our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2014. All
forward-looking statements contained in this release speak only as of
the date on which they were first made by us, and we undertake no
obligation to update such statements to reflect events that occur or
circumstances that exist after such date.
Source: Opexa Therapeutics, Inc.